IXC — Invex Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- AU$6.01m
- -AU$0.14m
- AU$1.26m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.166 | 0.159 | 0.262 | 1.26 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.232 | 3.53 | 2.44 | 4.22 | 9.01 |
Operating Profit | -0.232 | -3.36 | -2.28 | -3.95 | -7.75 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.232 | -3.36 | -2.28 | -3.95 | -7.75 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.232 | -3.36 | -2.28 | -3.95 | -7.75 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.232 | -3.36 | -2.28 | -3.95 | -7.75 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.232 | -3.36 | -2.28 | -3.95 | -7.75 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.002 | -0.055 | -0.03 | -0.053 | -0.103 |